Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF N581S NRAS Q61R |
Therapy | Dabrafenib + Trametinib |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF N581S NRAS Q61R | melanoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stability with shrinkage of metastatic lesions in a melanoma patient harboring BRAF N581S and NRAS Q61R (PMID: 36217799). | 36217799 |
PubMed Id | Reference Title | Details |
---|---|---|
(36217799) | BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors. | Full reference... |